Research Integrity & Compliance
Institutional Biosafety Committee
Registration Document for the Use of
Non-Exempt Recombinant DNA
USF requires that all recombinant DNA work conducted at or supported by USF or affiliated institutions
must be registered with and approved by the Institutional Biosafety Committee (IBC) prior to initiation of
the project.
Instructions:
1. If your recombinant DNA experiment meets the definition of any of the Non-Exempt categories
referenced in NIH guidelines (Section III-D) to complete this registration form.
2. Please provide complete information for every item. Blank or incomplete items may delay the
processing of your application.
3. Completed forms may be submitted by e-mailing an electronic copy to [email protected] and
include a scanned copy of the signed personnel and signature pages.
4. For more guidance, contact Farah Moulvi at (813) 974-0954 or Debbie Howeth at (813) 974-5091.
1.
Basic Information
1.1
Principal Investigator:
Department:
Building:
E-mail:
Office Phone(s):
PI’s Study Coordinator:
Coordinator’s E-mail:
1.2
1.3
Type of Registration:
Campus Mail:
Office Room#:
Fax:
Lab Phone:
Coordinator Phone:
Single Project
Multi-Project
New Registration
3rd Year Renewal Registration Replacing Previous IBC Study #
1.4
Project Title(s) (if multi-project, list titles of each project and assign a number to each):
1.5
Will this protocol use any VA Resources?
No.
Yes.
2.
Recombinant DNA Project Information
2.1 Very briefly summarize (in 150 words or less), in lay terms, the purpose/objectives of
this study:
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 1
2.2
3.
In order for the IBC to perform a biosafety risk assessment on this protocol, please
provide below or attach a one-page description of the specific experimental laboratory
procedures (e.g., culturing, vortexing, incubating, etc.) involving the
rDNA/biohazardous materials. Describe the procedures that will be done with the
rDNA/biohazardous agent in a chronological order from the beginning of the study to
its conclusion. Include any human subject/animal and/or human/animal tissue(s)
handling procedures that will be used during the experiment, if applicable.
Biosafety Procedures
3.1
Does the study involve the generation or use of more than 10 liters of culture?
No.
Yes. Note: This project may require review and approval by NIH/OBA.
Contact the USF Institutional Biosafety Officer at (813) 974-0954.
3.2
A. Indicate the types of experimental procedures which you will use that have the
potential to generate aerosols/splashes (check all that apply).
Homogenization
Centrifugation
Sonication
Dissection
Pipetting
Cell sorter and/or flow cytometry
Other procedures specific for your protocol: [Please specify]
None. Go to Question 3.3
B. What special practices/procedures will you use for containment of aerosols/splashes
for the above-mentioned experimental manipulations in Question 3.2?
3.3
Indicate the Safety Equipment you will use (check all that apply).
Stomachers
Safety Blender (e.g. shatter proof jar-double walled: blender rotors leak proof)
Low aerosolization pipette tips
Mechanical or electronic pipettors
Chemical fume hood (for chemical use only)
Centrifuge with safety cups or sealed rotor heads
Biological Safety Cabinet (BSC) - Must be certified annually
Date certified
Other: [Please specify]
None [Please explain/justifyspecify]
Use of Sharps
3.4 Indicate the Safety Practices to be used with Sharps (needles, scalpels, etc.).
Substitute glassware with plastic ware, when possible
Do not bend, break or recap needles
Do not bend, break or recap scalpels
Dispose of sharps in red sharps containers
I will/have consider(ed) the use of appropriate and effective sharps to eliminate or
minimize occupational exposure.
Not Applicable
NOTE: An engineered sharp has a physical attribute built into the sharp device that
effectively reduces the risk of an exposure incident. Examples of such devices include
retractable needles, hinged needle shields, needleless IV connectors, sliding sheath/sleeve and
needle guards.
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 2
3.5
Indicate the Personnel Protective Equipment that will be used (check all that apply).
Particulate respirators:
N 95 (HEPA)
N 100 (HEPA)
Face Shield
Lab Coats (front buttoned)
Safety Glasses/Goggles
Double gloves
Lab gown (Tie backs)
Gloves
Disposable Suits/coveralls with attached hood and boots
Other: [Please specify]
NOTE: Per OSHA regulations, the use of particulate masks, such as N-95, requires
medical evaluation, fit testing, and training prior to their use and on an annual basis.
4.
NIH Guidelines Determination
4.1
Which section of the NIH Guidelines does your research with recombinant or synthetic
nucleic acids involve: (select all that apply)
Deliberate transfer of a drug resistance trait to microorganisms that are not known
to acquire the trait naturally if such acquisition could compromise the use of the drug to
control disease. (Section III-A-1-a)
Cloning of toxin molecules with LD50 of less than 100 ng / kilogram body weight.
(Section III-B-1)
Experiments that involve the deliberate transfer of recombinant DNA, or DNA or
RNA derived from recombinant DNA, into one or more human research participant.
(Section III-C-1)
Experiments using Risk Group 2, 3, or 4 agents as host-vector systems. (Section IIID-1)
Experiments in which DNA from Risk Group 2, 3, or 4 agents is cloned into
nonpathogenic prokaryotic or lower eukaryotic host-vector systems. (Section III-D-2)
Experiments Involving the Use of Infectious DNA or RNA Viruses or Defective DNA
or RNA Viruses in the Presence of Helper Virus in Tissue Culture Systems (Section IIID-3)
Experiments that generate transgenic animals, including insects. (Section III-D-4)
Experiments involving viable rDNA/ or synthetic nucleic acids -modified
microorganisms tested on whole animals.(Section III-D-4)
Experiments involving whole plants that require BSL3 or BSL4 containment.
(Section III-D-5)
Experiments involving more than 10 liters of culture.(Section III-D-6)
Experiments involving human influenza strains H2N2, 1918 H1N1, and/or highly
pathogenic H5N1.(Section III-D-7)
None of the above
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 3
5.
Vector Backbone Information
5.1
Item
#
Type1
Provide all requested information for each rDNA vector that will be used in this
project in the table below.
Vector Name
(including Serotype
or strain if
applicable)
Source2
Risk
Group3
(RG)
Biosafety
Level3
(BSL)
Locations
of Use
(Building/
Room)
Locations of
Storage (if
different)
(Building/
Room)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
A=adenovirus, AAV=Adeno-associated virus, R=retrovirus, L=lentivirus, ONC=Oncoretrovirus, N=nonviral, O=other viral vector (please specify) 2 Specify the type and name of source (e.g., vendor – Clontech,
Invitrogen; off-campus collection – Univ. of CA).3 Refer to the NIH Guidelines, and the BMBL for RG and
BSL designation.
5.2 Are you using a replication competent virus? If so provide justification for its use.
5.3 Indicate the Biosafety Containment Level (BSL) ONLY if different than the BSL
specified in Table 4.1.
BSL-1
6.
BSL-2
BSL-3
Insert DNA Source
6.1
RCDC 001.15
Rev. 08/2016
Indicate the original source(s) of DNA you intend to clone (check all that apply).
Bacterial
Protozoan
Viral
Fungal
Human
Mammalian
Parasitic
Synthetic
Other: [Please specify]
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 4
6.2
Please list the insert DNA(gene) and the biological function of the gene product or
sequence that will be inserted, if applicable, the vendor/investigator from which the
DNA was acquired.
Protein
Full Name
Biological Function
Full Name
Biological Function
Category of
protein
For Example:
Protein
KRAS
6.3
RCDC 001.15
Rev. 08/2016
Category of
protein
Kirsten Rat
Ras proteins bind GDP/GTP and Oncogene
Sarcoma
possess intrinsic GTPase activity.
Viral
Oncogene Plays an important role in the
Homolog
regulation of cell proliferation
Can the expression of your gene product be harmful (e.g., toxic) in an unanticipated
exposure to humans, animals or plants?
No.
Yes. Do you anticipate a local or systemic expression?
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 5
7.
6.4
Is this gene involved in cell growth control and/or tumor induction (i.e., oncogene,
tumor suppressor, growth factor, cytokine, apoptosis inducer or inhibitor)?
No.
Yes.
6.5
Indicate the host (target recipient) of the vector-recombinant DNA combination by
checking all that apply.
Animals
Human
E. coli
Cell culture
Plants
Other: [Please specify]
6.6
Does the gene that you are cloning produce a toxin (e.g., microbial toxins such as
tetanus toxin, diphtheria toxin and Shigella dysenteriae neuro toxin) or is the toxin a
select agent (See Select Agent list )?
No.
Yes. Specify the toxin below. (Note: This project may require review and
approval by NIH/OBA. Contact the USF Institutional Biosafety Officer at (813)
974-0954.
6.7
Will there be transfer of a drug-resistance trait to microorganisms that are not known
to acquire that trait naturally, when such acquisition could compromise the use of a
drug to control disease agents in humans, animals, or plants?
No.
Yes. Please do A and B:
A. Contact the USF Institutional Biosafety Officer at (813) 974-0954.
B. Prior approval from the NIH/OBA Recombinant Advisory Committee (RAC)
is required. Attach a copy of the letter of approval from NIH/OBA.
Plants, Insects, Protozoans
7.1
Do you intend to transfer recombinant DNA into a germ line (permanent change) in
order to establish a transgenic plant line, insect, and/or protozoan?
No. Go to section 8.
Yes. What are the anticipated or known immediate/long-term adverse events
associated with the deliberate/accidental release of the transgenic plant, insect,
and/or protozoa to the environment?
7.2
What safety practices, safety equipment, and engineering control(s) are in place to
prevent the accidental and/or deliberate release of the transgenic plant, insect
and/or protozoa to the environment?
7.3
Will the project at any time require the release of an organism containing rDNA
molecules into the environment?
No.
Yes. (Note: This project may require review and approval by NIH/OBA. Contact
the USF Institutional Biosafety Officer at (813) 974-0954.
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 6
8.
9.
rDNA Cloning
8.1
Will rDNA cloning be done using human or animal pathogens as hosts to generate
mutated strains of these pathogens?
No.
Yes. Please describe the host-vector system which will be the recipient of the
rDNA
8.2
Will cloning be done using source DNA from human or animal pathogens that have
been classified as Risk Group 3, Risk Group 4, and/or Select Agents?
No.
Yes. (Note: This project may require review and approval by NIH/OBA. Contact
the USF Institutional Biosafety Officer at (813) 974-0954.)
Human Use
9.1
Will human subjects and/or human clinical specimens be used in any aspect of the
experiment?
No. Go to Section 10.
Yes.
9.2
Will there be transfer of DNA, recombinant DNA, or RNA derived from recombinant
DNA to human subject(s) (i.e., gene therapy)?
No.
Yes. If yes, submit these additional documents:
A. Review letter from NIH /OBA or, if selected for full RAC review, the RAC
review comments
B. Informed Consent Form
C. Clinical Protocol
D. Sponsor’s investigational brochure
9.3
If administering rDNA viral vectors into humans, are assay systems used to measure
the titer of replication competent viruses that may be present?
No. Please justify.
Yes. Describe the assay system and action plan if revertants are detected.
Not Applicable.
9.4
RCDC 001.15
Rev. 08/2016
Does the study involve the use of human cells and/or human clinical samples?
No.
Yes. List the type(s) of human clinical specimens you intend to use.
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 7
9.5 Has this research protocol been reviewed and approved by the IRB?
No. Date of Intended Submission to IRB: ________________
Yes. IRB study #: ________________ Date approved: ________________
Approval Pending - Date Submitted to IRB: ________________
10.
Animal Use
10.1 Will you administer recombinant DNA to animals or use animal tissue?
No. Go to Section 11.
Yes. Specify the animal species: ________________
10.2 Indicate the Animal Biosafety Level (ABSL) for housing animals after administration
of rDNA material.
Transduced cell lines verified by assay to be free of viral particles administered to
animals - ABSL-1. Please describe method how viral particles (both replication
competent and replication incompetent) will be excluded.
Transduced cell lines not verified by assay to be free of viral particles administered
to animals – ABSL-2 for duration of study.
Direct adenovirus or adeno-associated viral vector administration to animals ABSL-2 for 72 hours.
Direct administration of other viral vectors (e.g. Lentivirus, retrovirus) that are
co-administered with human cells to the animals - ABSL-2 for the duration of the
study.
Direct administration of other viral vectors (e.g. Lentivirus, retrovirus) that are
not co-administered with human cells to the animals - ABSL-2 for 7 days.
Administration of uncharacterized primary human explants to animals (e.g.
human tumors - ABSL-2 for the duration of the study.
Other: [Please explain/specify].
10.3 Will you insert recombinant DNA into a germ line (permanent change) in order to
establish a transgenic or gene-targeted animal?
No.
Yes. What are the anticipated or known immediate/long-term adverse effects or
changes in phenotype/or genotype (e.g., early disease onset/resistance,
immunodeficiency) of such a change on the animal?
10.4 List the animal facility (e.g., College of Medicine, Stabile Research Building, Byrd
Alzheimer’s Center, Psychology, College of Public Health) and the area/room
number(s) where the animals will be housed or used.
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 8
10.5 What kind of expression do you expect the recombinant DNA to exhibit in the
animal?
Transient in vivo expression (e.g., injection of plasmids or transfected cell line in
animal).
Permanent expression.
10.6 Route of agent administration.
Intravenous
Intraperitoneal
Other: [Please specify]
Subcutaneous
Intramuscular
10.7 Has this research protocol been reviewed and approved by the USF Institutional
Animal Care and Use Committee (IACUC)?
No. Date of Submission or Intended Submission to IACUC, include study # (if
known): ________________
Yes. IACUC study #: ________________ Date approved: ________________
Approval Pending –Study # and date Submitted to IACUC: ________________
10.8 Will the rDNA molecule and/or the organism containing the rDNA molecule present
any potential risk of exposure to animal care staff?
No. Go to Section 11.
Yes. Answer A, B, C, and D.
A. What animal sources/routes (e.g., urine, feces, blood, bite/scratch), that may
contain the rDNA microorganism or the product of the gene expressed,
present a potential risk of exposure to the animal care staff?
B. What Personal Protective Equipment is required to be worn by the animal
care staff to protect them from potential risk of exposure from the animal
source(s) mentioned in 9.9.A?
Standard ABSL-1 PPE (work uniform or disposable lab coat/gown, gloves
when handling animals)
Standard ABSL-2 PPE according to Comparative Medicine SOP 408
(gloves, disposable lab coat/gown, shoe covers)
Additional requirements.
N 95 (HEPA) Respirator
N 95 (HEPA) Respirator
Full Face Shield
Double gloves
Tyvek/Disposable Suits
N 100 (HEPA) Respirator
N 100 (HEPA) Respirator
Safety Glasses/Goggles
Special gloves [Please specify material]
Other: [Please specify]
Provide justification:
C. What safety practices are in place to protect the animal care staff from potential
risk of exposure from the animal source(s) mentioned in part A? If additional PPE
is required in section B (above), please specify the reason.
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 9
Comparative Medicine SOP 408 BSL-2 Rodent Husbandry is sufficient to
protect the animal care staff
Additional practices are required. [Please specify]
D. The IBC requires a minimum concentration of a 1:10 dilution of standard
household bleach (5.25% sodium hypochlorite) as the primary disinfectant. If
using this bleach solution as the primary disinfectant check this box.
1:10 dilution (1 part bleachand 9 parts water) of standard household
bleach (5.25% sodium hypochlorite) to water. Made fresh at least weekly and
stored in opaque containers or Clidox S 1:5:1 used in accordance with
Comparative Medicine SOP 408.
If using an alternative disinfectant, specify in box below, the name, active
ingredient, concentration and an exemption for use of this disinfectant.
NOTE: Unless noted on this application with justification/explanation and approval by the
IBC, all other disinfectants (e.g., 70% alcohol) are secondary disinfectants to be used after
the 10% bleach.
11.
Medical Information
11.1 Please list risks of disease and/or adverse effects (e.g. – altered immune
response/immunosuppression/allergenicity/toxicity) to humans, animals, and/or plants
that might result from exposure to the organisms or viruses containing recombinant
DNA molecules? Please be aware that exposure to retroviral and lentivitral vectors
may theoretically, although extremely rare, lead to insertional mutagenesis.
11.2
By checking this box, I affirm that in the case of an exposure incident my
laboratory personnel (Faculty, staff, students and visitors) have been instructed to
follow the Exposure Management Plan as described below:
USF Personnel
1. Contact AmeriSys at 1-800-455-2079 (24 hours a day/7 days per week) --During working hours (M-F, 8 – 5 PM) the USF Worker’s Compensation
Administrator Meica Elridge should also be contacted at (813) 974-5775, or
([email protected]).
2. In the event that follow-up is necessary following initial care from the USF
Workers’ Compensation Provider, please contact the USF Medical Health
Administration (Employee Health) office at (813) 974-3163, or pager (813) 2160153.
3. Notify the Biosafety Officer at (813) 974-0954 or after hours at (813) 469-1625
Moffitt Personnel:
Moffitt Incidents Website per Moffitt Work Related Injury policy EH-13
Notify the Biosafety Officer at (813) 974-0954 or after hours at (813) 469-1625
If you have a protocol specific exposure management plan which is different than
above, describe in the space provided below.
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 10
11.3
By checking this box, I affirm that I will provide protocol/procedure specific
training for personnel working with organisms or viruses containing recombinant
DNA molecules and inform them of any potential hazards/risks including an
immunocological condition which may increase the risk of infection. They will also
be instructed and trained in lab-specific clean up procedures for biohazardous spills
and PI provided laboratory specific training?
NOTE: For general biohazard spill procedures access the following website
http://www.research.usf.edu/dric/biosafety/resources.asp .
12.
Decontamination and Disposal
12.1 The IBC requires a minimum concentration of a 1:10 dilution of standard household
bleach (5.25% sodium hypochlorie) as the primary disinfectant. If using this bleach
solution as the primary disinfectant check this box.
1:10 dilution (1 part bleach and 9 parts water) This needs to be made fresh
at least weekly and preferably stored in opaque containers)
If using an alternative disinfectant, specify in box below, the name, active
ingredient, concentration and an exemption for use of this disinfectant.
NOTE: Unless noted on this application with an explanation and approved by the IBC, all
other disinfectants (e.g., 70% alcohol) are secondary disinfectants to be used after the 1:10
dilution of bleach.
13.
12.2
Indicate how biohazardous solid waste will be decontaminated and disposed.
Autoclaved Time:
minutes
Temp:
Celsius
(recommended 121C, 15 p.s.i. for 30 minutes minimum)
Chemically inactivated: [Please specify]
Packaged as biohazardous waste per USF/Moffitt policy
Other: [Please specify]
12.3
Indicate how biohazardous liquid waste will be decontaminated and disposed.
Autoclaved Time:
minutes
Temp:
Celsius
Chemically inactivated: [Please specify]
Packaged as biohazardous waste per USF/Moffitt policy
Other: [Please specify]
Storage and Transport
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 11
13.1
Will the organism harboring the rDNA used/generated in these experiments be
transported or transferred outside of the room in which they are stored?
No.
Yes. Answer A and B below.
A. To what location(s) outside of your laboratory will you transport/transfer these
recombined biological materials?
B. When transporting/transferring materials, the materials must be placed inside
a watertight primary container, which is then placed into a watertight, leak proof
and durable secondary container for transportation, with absorbent material
placed between the two containers to absorb contents of the container in case of
possible spill.
I attest that materials will be transported in accordance with the above
described procedure.
13.2
Will any of these organisms and/or viruses containing recombinant DNA be shipped
via commercial carrier (e.g., Federal Express)?
No.
Yes. Identify the person(s) that will be preparing the recombinant DNA molecules
for shipping and provide their Transportation of Dangerous Goods training dates.
13.3
Will any of these materials be imported from or exported to one or more foreign
countries?
No.
Yes. All shipments must meet federal and state transportation regulations and
USF policies. Respond to A, B, C, and D below:
A. List the materials to be imported and/or exported.
B. List the country of origin or destination for each.
C. Indicate whether this is a one-time shipment or part of a series of shipments.
D. Attach a copy of the USDA permit, CDC permit, and/or Dept. of Commerce
permit.
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 12
14.
Personnel
The Institutional Biosafety Committee (IBC) must be notified of any new personnel who will be directly involved in the conduct of the
experiment and/or for whom a potential risk exists by virtue of their presence within the research environment.
14.1 List the names of all personnel involved and have each person initial the following assurance:
 I have read and understand the nature of these experiments.
 I have the knowledge and training required to safely handle the materials described.
 I agree to conduct these experiments in accordance with all USF IBC policies and the USF Biosafety Manual:
 http://www3.research.usf.edu/dric/biosafety/docs/biosafety-manual.pdf
 I have attended/will attend the annual USF biosafety training indicated.*
Name
Initial
here
Date
Biosafety
Training*
Most current
training Date
E-mail
Occupational Health Evaluation
Completed
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
Yes
No
Yes
No
NA
*
The following types of training classes are required:
 Core – Must be completed by those who have not completed it previously.
 Continuing Education – Must be completed annually.
 Special Topics – Required for persons involved in certain types of work.
For current Biosafety training information, please go to: http://www3.research.usf.edu/dric/biosafety/education.asp
RCDC 001.15
Rev. 08/2016
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 13
15.
Laboratory Inspection
BSL-2 or BSL-3 laboratories must pass inspection before initial approval for research
activities can be granted for this proposed study. The Principal Investigator is responsible for
scheduling an inspection by contacting the Biosafety Staff at [email protected] or (813) 9745091 or (813) 974-5110.
Information on biosafety containment levels and other guidance is available in the NIH
Guidelines for Research Involving Recombinant DNA Molecules, the Biosafety in
Microbiological and Biomedical Laboratories, 5th Edition , and the USF Institutional Biosafety
Manual. Investigators are encouraged to consult these sources to ensure that their
laboratories meet the required standards for sound biosafety practices.
A Sample BSL-2 Checklist is provided to help you prepare for a laboratory inspection.
15.1 Please provide the date of your last Biosafety lab inspection.
16.
Investigator Assurance
 I agree to use lab practices that meet the biosafety level (BSL) specified in this
application.
 I will begin the work described only after obtaining approval of the IBC and will notify
the IBC of any changes in the approved application.
 I will report any and all accidents/exposures or illnesses related to this work to the IBC
in a timely fashion.
 I understand the NIH Guidelines as they pertain to the research described and will
conduct this research in compliance with these regulations.
 I have the knowledge and training required to safely handle the materials described.
 I acknowledge my responsibility for the conduct of this research in accordance with
University Policy and the USF Institutional Biosafety Manual .
 I acknowledge my responsibility to secure and control the biological agents used in this
project.
 I will train all staff on laboratory specific procedures
____________________________________________
Signature of Principal Investigator
RCDC 001.15
Rev. 08/2016
___________________
Date
Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
USF Institutional Biosafety Committee
Page 14
Appendix A – Biosafety References






Biosafety in Microbiological and Biomedical Laboratories, 5th Edition
Material Safety Data Sheets (MSDS) for Infectious Agents
Risk Group Classification for Infectious Agents
USF Institutional Biosafety Manual
NIH Guidelines for Research Involving rDNA Molecules
Biological Spill Response
RCDC 001.12 Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
Rev. 06/2014
USF Institutional Biosafety Committee
Page i
Appendix B – Response to Exposure/Accident for Laboratories Working with
Biohazards [USF Personnel]
The following emergency response procedures shall be followed when a worker has been potentially
exposed to infectious agents including blood borne pathogens via a needle-stick, cut, animal bite, or
scratch, via mucous membrane contact, or via non-intact skin contact to ensure prompt and appropriate
care. Some post-exposure treatments must be started within 1-2 hours of exposure so time is critical.
If accidental exposure occurs:
 The exposed site must be washed immediately for 10 minutes
- If needle-stick, cut, animal bite or scratch, wash with soap and water after allowing the
wound to bleed freely. Apply an appropriate skin disinfectant if applicable.
- If mucous membrane (eyes, nose, mouth) flush with water at the nearest faucet or eye wash
station for at least 15 minutes.
- If non-intact skin contact (cuts, rash, eczema, or dermatitis) wash with soap and water. Apply
an appropriate skin disinfectant if applicable.
 Remove contaminated clothing.
 In the case of an emergency call 911.
 Report all work related injuries and/or work related illnesses immediately to their supervisor/lab
director/PI. Call AmeriSys as soon as practical at 1(800) 455-2079 to report the work-related
injury or illness.
 Call Biosafety officer at 974-0954 about the cause of the lab accident/potential exposure and the
organisms involved.
 If exposed to a blood borne pathogen contact the USF Health Medical Health Administration
Office at (813) 974-3163 or by pager at (813) 216-0153 during regular working hours. Contact
the “on-call” Infectious Disease Physician at (813) 974-2201 after-hours and on weekends.
If you become ill or injured on the job:
An employee who becomes ill or is injured as the result of a job-related incident must report the incident
to the supervisor immediately no matter how minor the injury may appear to be.
If you are the supervisor:
When an employee reports a work-related injury or illness, take prompt action to:
1. Ensure the employee receives necessary medical attention. In case of emergency, call 911 or
immediately send the employee to a hospital emergency room. Call AmeriSys as soon as practical at
1(800) 455-2079 to report the work-related injury or illness.
2. With the injured or ill employee, immediately call AmeriSys 1(800) 455-2079 to report the workrelated injury or illness so the employee can receive appropriate care. Except in cases of emergency, the
injured or ill employee must be present with the supervisor when the injury or illness is reported.
3. Complete the Supervisors Incident/Injury Report and forward to Human Resources within 24 hours.
4. Take action to correct any safety hazards to prevent the same or similar injury or illness from
occurring again.
All work-related injuries or illnesses are to be reported by the supervisor or department designee by
telephone to: AmeriSys 1(800) 455-2079 (toll free). For additional information on how to report a workrelated injury or illness go to the USF Worker’s Compensation website at: http://usfweb2.usf.edu/humanresources/employee-relations/workers-comp.asp. You may also contact Workers’ Compensation
Administrator Meica Eldridge at (813) 974-5775 or [email protected]. Reports may be faxed to (813)
974-9346.
RCDC 001.12 Registration Document for the Non-Exempt Use of Recombinant DNA in Experiments
Rev. 06/2014
USF Institutional Biosafety Committee
Page ii